<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286958</url>
  </required_header>
  <id_info>
    <org_study_id>HRHB-CE001</org_study_id>
    <nct_id>NCT04286958</nct_id>
  </id_info>
  <brief_title>A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC</brief_title>
  <acronym>ESCC</acronym>
  <official_title>A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy and safety of patients who receive&#xD;
      camrelizumab as consolidation therapy after radical concurrent chemoradiotherapy in locally&#xD;
      advanced ESCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, 40 patients with locally advanced ESCC will be enrolled. All patients who had&#xD;
      received radical concurrent chemoradiotherapy were treated with camrelizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>evaluated in 24 months since the treatment began</time_frame>
    <description>Baseline to measured date of progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>tumor assessment every 6 weeks since the treatment began，up to 24 months</time_frame>
    <description>Baseline to measured stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durarion of response (DOR)</measure>
    <time_frame>tumor assessment every 6 weeks since the treatment began，up to 24 months</time_frame>
    <description>From the first assessment to CR or PR to the first assessment to PD or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>the first day of treatment to death or last survival confirm date,up to 24 months</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. The number of Participants with adverse events will be recorded at each treatment visit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Relationship between tumor markers and efficacy in tumor tissues and peripheral blood (including but not limited to PD-L1, TMB, etc.)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients who had received radical concurrent chemoradiotherapy were treated with camrelizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)</description>
    <arm_group_label>Camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age:18 to 75 years old;&#xD;
&#xD;
          2. Histology confirmed as esophageal squamous cell carcinoma;&#xD;
&#xD;
          3. T1bN+M0, T2-4N0-2M0 local progress period;&#xD;
&#xD;
          4. Have previously received radical concurrent chemoradiotherapy;&#xD;
&#xD;
          5. According to RECIST 1.1, at least one measurable lesion;&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;&#xD;
&#xD;
          7. Expected survival period ≥ 12 weeks;&#xD;
&#xD;
          8. Major organ function has to meet the following certeria:&#xD;
&#xD;
        1)For results of blood routine test HB≥90g/L; ANC≥1.5×109/L; PLT≥80×109/L; 2)For results of&#xD;
        blood biochemical test ALB≥30g/L; ALT and AST&lt;2.5×ULN; TBIL≤1.5ULN; Serum creatinine&#xD;
        ≤1.5ULN; 9. Left ventricular ejection fraction (LVEF) ≥50%; 10. Women of childbearing age&#xD;
        must have contraceptive measures or have test pregnancy (serum or urine) enroll the study&#xD;
        before 14 days, and the results must be negative, and take the methods of contraception&#xD;
        during the test and the last to have drugs after 8 weeks. Men must be contraception or has&#xD;
        sterilization surgery during the test and the last to have drugs after 8 weeks; 11.&#xD;
        Participants were willing to join in this study, and written informed consent, good&#xD;
        adherence, cooperate with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with immunosuppressive medications within 14 days of first administration of&#xD;
             study treatment, excluding nasal spray and inhaled corticosteroids or physiological&#xD;
             doses of systemic steroid hormones (no more than 10 mg / day of prednisolone or other&#xD;
             corticosteroids of equivalent pharmaceutical physiological dose);&#xD;
&#xD;
          2. The patient has any active autoimmune disease or a history of autoimmune disease (such&#xD;
             as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia,&#xD;
             uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis,&#xD;
             Hyperthyroidism; patients with vitiligo; Asthma has been completely relieved in&#xD;
             childhood, and patients who do not need any intervention after adulthood can be&#xD;
             included; asthma patients who require bronchodilators for medical intervention cannot&#xD;
             be included);&#xD;
&#xD;
          3. Patients with other malignant tumors within 5 years (except for the treated skin basal&#xD;
             cell carcinoma and cervical carcinoma in situ);&#xD;
&#xD;
          4. Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome&#xD;
             (AIDS), active hepatitis B (HBV-DNA ≥1000 IU/ml) or hepatitis C (positive hepatitis C&#xD;
             antibody, and HCV-RNA is higher than the lower limit of detection of the analytical&#xD;
             method) or co-infection with hepatitis B and C, requiring antiviral treatment during&#xD;
             the study ; 5.6 months before study drug administration, the following occurred:&#xD;
             myocardial infarction, severe / unstable angina pectoris, grade III-IV cardiac&#xD;
             insufficiency according to New York Heart Association(NYHA) criteria, uncontrolled&#xD;
             arrhythmias (including QTcF interval male&gt; 450 ms, female&gt; 470 ms ,The QTcF interval&#xD;
             is calculated using Fridericia formula), symptomatic congestive heart failure,&#xD;
             cerebrovascular accidents (including transient ischemic attack or symptomatic&#xD;
             pulmonary embolism);&#xD;
&#xD;
        6.Severe infections within 4 weeks before study drug administration (eg. Need intravenous&#xD;
        drip antibiotics, antifungals or antivirals) or Unexplained fever&gt;38.5℃ during screening&#xD;
        visits or on the first scheduled day of dosing; 7.History of allogeneic organ&#xD;
        transplantation or allogeneic hematopoietic stem cell transplantation; 8.Less than 4 weeks&#xD;
        from the last clinical trial; 9.History of psychiatric drugs abuse and can't quit or&#xD;
        patients with mental disorders; 10.The researchers think inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JUN WANG, Ph.D</last_name>
    <phone>13931182128</phone>
    <email>wangjunzr@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>Jun wang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

